Rising healthcare costs impoverish 75 lakh families annually: Minister

‘Conditions are so bad that children have to stop their education in some extreme cases’

July 09, 2019 10:18 pm | Updated 10:40 pm IST - New Delhi

Mansukh L. Mandaviya.

Mansukh L. Mandaviya.

The Central government has admitted that 75 lakh families fall below the poverty line annually due to the rising cost of health care in India.

Replying to a question on the availability and price control on generic drugs Mansukh L. Mandaviya, MoS, Chemical and Fertilizers said: “Annually we are seeing families slipping below the poverty line because of the escalating costs of health care and medicines in India. Conditions are so poor that children have to stop their education in some extreme cases. It is vital that this fall is netted immediately.’’

He informed the House that the Central government is providing generic medicines under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) which are normally cheaper by 50-90% of average price of top 3 brands of corresponding medicines.

“A total 5,028 PMBJP Kendras have been opened across the country, where 714 of the 900 medicines in the product basket of PMBJP is currently available,’’ said the Minister.

He explained that the product basket of PMBJP now comprises 900 medicines and 154 surgicals and consumable items. Out of this, 714 medicines and 53 surgicals are now available for sale at PMBJP Kendras.

“The purchase orders for procurement of 24 medicines and 90 surgical items have already been issued and these medicines/surgicals will be available for sale at PMBJP Kendras in the next two months. For 162 medicines and 11 surgical items, no bids were received in the last two tenders. Floating tenders for required medicines is an ongoing process,’’ noted the reply by the Minister.

The National Pharmaceutical Pricing Authority (NPPA), he said, fixes the ceiling price of scheduled medicines specified in the first schedule of the Drugs (Prices Control) Order, 2013 (DPCO) in accordance with the provisions of the DPCO.

“All manufacturers of scheduled medicines (branded or generic) have to sell their products within the ceiling price (plus applicable local taxes) fixed by the NPPA. A manufacturer is at liberty to fix the maximum retail price of a non-scheduled formulation (branded or generic) launched by it. However, as per the DPCO, the manufacturers of non-scheduled formulations are not allowed to increase the maximum retail price of such formulations by more than 10 % per annum,’’ he explained.

Top News Today


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.